India Crypto Exchange

Best Bitcoin Trading Platform

Tag Archive : market news

Buy The Ramco Cements, target price Rs 1110: Edelweiss

Edelweiss has buy call on The

Ramco Cements

Ltd. with a target price of Rs 1110. The current market price of The Ramco Cements is Rs 1067.85.

Time period given by analyst is Intra Day when The Ramco Cements Ltd. price can reach defined target.
The Ramco Cements Ltd., incorporated in the year 1957, is a Large Cap company (having a market cap of Rs 25188.68 Crore) operating in Cement sector.

Stock Analysis – Know before investing

Stock score of Ramco Cements Ltd moved up by 2 in a week on a 10-point scale.

Subscribe Now

Exclusively for

Stock Analysis

Stock score of Ramco Cements Ltd is 8 on a scale of 10. View Stock Analysis »

The Ramco Cements Ltd. key Products/Revenue Segments include Cement, Power, Dry Mortar Mix, Scrap, Ready Mix Concrete and Other Operating Revenue for the year ending 31-Mar-2021.

Financials
For the quarter ended 30-09-2021, the company reported a Consolidated Total Income of Rs 1510.33 Crore, up 21.80 % from last quarter Total Income of Rs 1239.99 Crore and up 18.60 % from last year same quarter Total Income of Rs 1273.47 Crore. Company reported net profit after tax of Rs 519.12 Crore in latest quarter.

Investment Rationale
Ramco Cement has formed a triple bottom pattern at levels of 920.

Promoter/FII Holdings
Promoters held 42.52 per cent stake in the company as of 30-Sep-2021, while FIIs owned 8.71 per cent, DIIs 31.68 per cent.

Buy Tata Motors, target price Rs 522: ICICI Direct

ICICI Direct has buy call on Tata Motors with a target price of Rs 522. The current market price of Tata Motors Ltd. is Rs 485.7.

Time period given by analyst is Intra Day when Tata Motors Ltd. price can reach defined target.

Tata Motors Ltd., incorporated in the year 1945, is a Large Cap company (having a market cap of Rs 160603.29 Crore) operating in Auto sector.

Tata Motors Ltd. key Products/Revenue Segments include Motor Vehicles, Spare Parts & Others, Miscellaneous Goods, Other Operating Revenue and Sale of services for the year ending 31-Mar-2021.

Financials
For the quarter ended 30-09-2021, the company reported a Consolidated Total Income of Rs 62245.73 Crore, down -7.08 % from last quarter Total Income of Rs 66988.05 Crore and up 14.92 % from last year same quarter Total Income of Rs 54163.22 Crore. Company reported net profit after tax of Rs -4476.61 Crore in latest quarter.

Investment Rationale
Bullish Pennant continuation pattern offers fresh entry opportunity, MACD in buy mode.

Promoter/FII Holdings
Promoters held 46.41 per cent stake in the company as of 30-Sep-2021, while FIIs owned 13.35 per cent, DIIs 13.3 per cent.

Add Ajanta Pharma, target price Rs 2440: HDFC Securities

HDFC Securities has add call on

Ajanta Pharma

with a target price of Rs 2440. The current market price of Ajanta Pharma Ltd. is Rs 2136.05. Time period given by analyst is one year when Ajanta Pharma Ltd. price can reach defined target. .

Ajanta Pharma Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 18342.12 Crore) operating in Pharmaceuticals sector.

Ajanta Pharma Ltd. key Products/Revenue Segments include Pharmaceutical Products, Export Incentives and Other Operating Revenue for the year ending 31-Mar-2021.

Stock Analysis – Know before investing

Stock score of Ajanta Pharma Ltd moved down by 1 in a month on a 10-point scale.

Subscribe Now

Exclusively for

Stock Analysis

Stock score of Ajanta Pharma Ltd is 7 on a scale of 10. View Stock Analysis »

Financials
For the quarter ended 30-09-2021, the company has reported a Consolidated Total Income of Rs 914.34 Crore, up 17.13 % from last quarter Total Income of Rs 780.62 Crore and up 26.86 % from last year same quarter Total Income of Rs 720.76 Crore. Company has reported net profit after tax of Rs 195.94 Crore in latest quarter.

Investment Rationale
Ajanta’s Q2 revenue/EBITDA came in 8%/9% ahead of expectations, primarily on account of robust growth in Indian and African businesses. EBITDA margin, at 29.7%, was broadly in line as higher other expenses were offset by savings in staff cost. The company has guided towards higher opex of ~INR2.25bn per quarter vs. the average run-rate of ~INR2bn in preceding quarters, which is likely to offset some benefits on account of operating leverage. However, the growth outlook for the branded generic business, such as the India, Africa (outperformance to continue) and US generics business (new launches led), remains strong. The brokerage expects 15%/16% revenue/EPS CAGRs over FY21-24e. It revises EPS by 4%/-5% for FY22/23 to factor in Q2 beat/ margin moderation and roll forward to Sep’23 EPS to arrive at a TP of INR2,440/sh, based on 23x Sep’23e EPS.

Promoter/FII Holdings
Promoters held 70.34 per cent stake in the company as of 30-Sep-2021, while FIIs owned 8.72 per cent, DIIs 12.07 per cent.

Buy Cipla, target price Rs 1120: Centrum Broking

Centrum Broking has buy call on

Cipla

with a target price of Rs 1120. The current market price of Cipla Ltd. is Rs 897.35. Time period given by analyst is one year when Cipla Ltd. price can reach defined target.

Cipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 72586.73 Crore) operating in Pharmaceuticals sector.

Cipla Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue, Export Incentives, Royalty Income and Scrap for the year ending 31-Mar-2021.

Stock Analysis – Know before investing

Stock score of Cipla Ltd moved down by 2 in a month on a 10-point scale.

Subscribe Now

Exclusively for

Stock Analysis

Stock score of Cipla Ltd is 6 on a scale of 10. View Stock Analysis »

Financials
For the quarter ended 30-09-2021, the company reported a Consolidated Total Income of Rs 5580.47 Crore, up .20 % from last quarter Total Income of Rs 5569.28 Crore and up 9.60 % from last year same quarter Total Income of Rs 5091.76 Crore. Company reported net profit after tax of Rs 712.00 Crore in latest quarter.

Investment Rationale
India business could post market-beating growth in FY22 while US business is expected to post faster ramp-up starting 2HFY23, with new launches like aAbraxane, gAdvair and gRevlimed. Considering lower R&D spend, given that major trials have been completed, along with consistent cost optimization, we expect better earnings trajectory. We look forward to (1) opportunities from inhaler – gAdvair filed in May 2020; (2) biosimilar product filings; (3) China market entry, focused on respiratory segment – more of H2FY22 opportunity. The brokerage maintains multiple at 26x average of FY23E & FY24E EPS, marginally changed FY22/FY23E earnings, and introduced FY24E. BUY with a TP of Rs1,120. At CMP of Rs917, the stock trades at 22.8x FY23E EPS of Rs40.1 and 19.4x FY24E EPS of Rs47.2.

Promoter/FII Holdings
Promoters held 36.12 per cent stake in the company as of 30-Sep-2021, while FIIs owned 28.1 per cent, DIIs 17.74 per cent.

Buy Tata Motors, target price Rs 546: Yes Securities

Yes Securities has buy call on

Tata Motors

with a target price of Rs 546. The current market price of Tata Motors Ltd. is Rs 508.6.

Time period given by analyst is Intra Day when Tata Motors Ltd. price can reach defined target.
Tata Motors Ltd., incorporated in the year 1945, is a Large Cap company (having a market cap of Rs 168887.45 Crore) operating in Auto sector.

Stock Analysis – Know before investing

Stock score of Tata Motors Ltd moved down by 2 in a month on a 10-point scale.

Subscribe Now

Exclusively for

Stock Analysis

Stock score of Tata Motors Ltd is 8 on a scale of 10. View Stock Analysis »

Tata Motors Ltd. key Products/Revenue Segments include Motor Vehicles, Spare Parts & Others, Miscellaneous Goods, Other Operating Revenue and Sale of services for the year ending 31-Mar-2021.

Financials
For the quarter ended 30-06-2021, the company reported a Consolidated Total Income of Rs 66988.05 Crore, down -25.00 % from last quarter Total Income of Rs 89319.34 Crore and up 105.55 % from last year same quarter Total Income of Rs 32589.59 Crore. Company reported net profit after tax of Rs -4320.60 Crore in latest quarter.

Investment Rationale
The stock is on the verge of a breakout from a sideways consolidation phase suggesting bullishness building up here. Further, RSI has turned higher from the previous reversal zone of 65 confirming the bullishness.

Promoter/FII Holdings
Promoters held 46.41 per cent stake in the company as of 30-Sep-2021, while FIIs owned 13.35 per cent, DIIs 13.3 per cent.

Buy Axis Bank, target price Rs 835: Kotak Securities

Kotak Securities Limited has buy call on Axis Bank with a target price of Rs 835. The current market price of Axis Bank Ltd. is Rs 808.95.

Time period given by analyst is Intra Day when Axis Bank Ltd. price can reach defined target.

Axis Bank Ltd., incorporated in the year 1993, is a banking company (having a market cap of Rs 247723.61 Crore).

Axis Bank Ltd. key Products/Revenue Segments include Interest & Discount on Advances & Bills, Income From Investment, Interest and Interest On Balances with RBI and Other Inter-Bank Funds for the year ending 31-Mar-2021.

Financials
For the quarter ended 30-06-2021, the company reported a Consolidated Total Income of Rs 20285.41 Crore, down -3.53 % from last quarter Total Income of Rs 21028.45 Crore and up 4.23 % from last year same quarter Total Income of Rs 19461.77 Crore. The bank reported net profit after tax of Rs 2356.91 Crore in latest quarter.

Investment Rationale
Hammer candlestick near short-term moving average suggests bullish momentum to persist.

Promoter/FII Holdings
Promoters held 11.64 per cent stake in the company as of 30-Sep-2021, while FIIs owned 54.53 per cent, DIIs 22.17 per cent.

Hold Indus Towers, target price Rs 305: Emkay Global

Emkay Global has hold call on Indus Towers with a target price of Rs 305. The current market price of Indus Towers Ltd. is Rs 270.

Time period given by analyst is one year when Indus Towers Ltd. price can reach defined target.

Indus Towers Ltd., incorporated in the year 2006, is a Large Cap company (having a market cap of Rs 74097.29 Crore) operating in Telecommunications sector.

Indus Towers Ltd. key Products/Revenue Segments include Income from Infrastructure Activity for the year ending 31-Mar-2021.

Financials
For the quarter ended 30-09-2021, the company reported a Consolidated Total Income of Rs 6969.20 Crore, up 1.68 % from last quarter Total Income of Rs 6853.90 Crore and up 289.65 % from last year same quarter Total Income of Rs 1788.60 Crore. Company reported net profit after tax of Rs 1558.50 Crore in latest quarter.

Investment Rationale
The recently announced telecom relief package by the government and the moderation in tenancy exits have removed the risk to revenues as well as the overhang on the stock (up 26% in the last three months). However, the continued increase in receivables (50% rise in H1FY22) points to the weak financial position of VIL. The brokerage continues to highlight that VIL will have to bring its house in order with fresh funding and tariff hikes before it starts investing in network expansion, which could potentially lead to tenancy additions for Indus. Until then, it believes that Bharti will remain the key contributor to tenancy growth, with single tenancy tower additions. It has raised FY22E revenue assumptions due to the inflation in diesel prices, while largely retaining revenue estimates for FY23-24. However, it has revised bottom-line projections upward by 2-4% due to lower depreciation charges. Key risks: 1) aggressive 4G expansion for independent sites; 2) robust growth from Jio; 3) shift to 5G, leading to fresh investments; 4) improvement in VIL’s financials; and 5) new revenue sources such as smart cities.

Promoter/FII Holdings
Promoters held 69.85 per cent stake in the company as of 30-Sep-2021, while FIIs owned 29.1 per cent, DIIs 0.35 per cent.

Buy Indian Bank, target price Rs 205: HDFC Securities

HDFC Securities has buy call on

Indian Bank

with a target price of Rs 205. The current market price of Indian Bank is Rs 181.55.

Time period given by analyst is six months when Indian Bank price can reach defined target.

Indian Bank, incorporated in the year 1907, is a banking company (having a market cap of Rs 21695.58 Crore).

Stock Analysis – Know before investing

Stock score of Indian Bank moved up by 3 in 3 months on a 10-point scale.

Subscribe Now

Exclusively for

Stock Analysis

Stock score of Indian Bank is 10 on a scale of 10. View Stock Analysis »


Indian Bank key Products/Revenue Segments include Interest & Discount on Advances & Bills, Income From Investment, Interest On Balances with RBI and Other Inter-Bank Funds and Interest for the year ending 31-Mar-2021.

Financials
For the quarter ended 30-06-2021, the company reported a Consolidated Total Income of Rs 11608.53 Crore, up 8.24 % from last quarter Total Income of Rs 10724.53 Crore and up .45 % from last year same quarter Total Income of Rs 11556.09 Crore. The bank reported net profit after tax of Rs 1259.82 Crore in latest quarter.

Investment Rationale
Primary trend of the stock has been bullish with higher tops and higher bottoms

Promoter/FII Holdings
Promoters held 79.86 per cent stake in the company as of 30-Sep-2021, while FIIs owned 2.41 per cent, DIIs 10.52 per cent.

Buy LIC Housing Finance, target price Rs 530: Emkay Global

Emkay Global has buy call on

LIC Housing

Finance with a target price of Rs 530. The current market price of LIC Housing Finance Ltd. is Rs 400.

Time period given by analyst is one year when LIC Housing Finance Ltd. price can reach defined target.

LIC Housing Finance Ltd., incorporated in the year 1989, is a Large Cap company (having a market cap of Rs 22470.07 Crore) operating in NBFC sector.

Stock Analysis – Know before investing

Stock score of LIC Housing Finance Ltd moved down by 2 in a week on a 10-point scale.

Subscribe Now

Exclusively for

Stock Analysis

Stock score of LIC Housing Finance Ltd is 3 on a scale of 10. View Stock Analysis »

Financials
For the quarter ended 30-09-2021, the company reported a Consolidated Total Income of Rs 4722.93 Crore, down -2.96 % from last quarter Total Income of Rs 4867.22 Crore and down -5.31 % from last year same quarter Total Income of Rs 4987.64 Crore. Company reported net profit after tax of Rs 249.86 Crore in latest quarter.

Investment Rationale
The brokerage values LICHF at 1.0x Sep’23E BVPS, using the excess-returns-on-equity method for FY23-24E RoE of ~13.5-14%. Its TP of Rs 530 implies a 30% upside from the current price.

Promoter/FII Holdings
Promoters held 45.24 per cent stake in the company as of 30-Sep-2021, while FIIs owned 24.07 per cent, DIIs 14.96 per cent.

Add Symphony, target price Rs 1300: HDFC Securities

HDFC Securities has add call on

Symphony

with a target price of Rs 1300. The current market price of Symphony Ltd. is Rs 1068.4.

Time period given by analyst is one year when Symphony Ltd. price can reach defined target.

Symphony Ltd., incorporated in the year 1988, is a Mid Cap company (having a market cap of Rs 7460.91 Crore) operating in Consumer Durables sector.

Stock Analysis – Know before investing

Stock score of Symphony Ltd moved down by 1 in a month on a 10-point scale.

Subscribe Now

Exclusively for

Stock Analysis

Stock score of Symphony Ltd is 6 on a scale of 10. View Stock Analysis »


Symphony Ltd. key Products/Revenue Segments include Air Coolers, Others and Other Operating Revenue for the year ending 31-Mar-2021.

Financials
For the quarter ended 30-09-2021, the company reported a Consolidated Total Income of Rs 229.00 Crore, down -3.78 % from last quarter Total Income of Rs 238.00 Crore and up 15.08 % from last year same quarter Total Income of Rs 199.00 Crore. Company has reported net profit after tax of Rs 30.00 Crore in latest quarter.

Investment Rationale
Symphony’s domestic business remained under pressure due to high trade inventory. Domestic revenue was at INR 1,350mn (HSIE INR 1,446mn), up 29% YoY, down 15% on a two-year CAGR. The company remained optimistic and is focusing on new launches and initiatives to revive domestic business. Performance in stable summer season will reflect the outcome of such efforts. Exports remained volatile on a quarterly basis, registering revenue of INR 50mn (HSIE INR 95mn) with RoW revenue down 1% YoY (non-seasonal quarter). Gross margin expanded 36bps YoY (+103bps in Q2FY21, +212bps in Q1FY22, HSIE -21bps) to 48.6%. EBITDA margin came in at 25% (HSIE 24.3%), growing 21% YoY (HSIE 29%). CT saw recovery in operating profitability in H1FY22 after showing dismal margin last year. IMPCO, too, saw margin recovery, while GSK China remained weak. Given the company’s leadership position and innovative product pipeline, the brokerage believes it is well positioned to gain from a strong season (missed the last two seasons). It values the stock at 35x P/E on 24E EPS and derive a TP of INR 1,300.

Promoter/FII Holdings
Promoters held 73.25 per cent stake in the company as of 30-Sep-2021, while FIIs owned 4.25 per cent, DIIs 9.46 per cent.